The Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
American Society of Hematology. (2022).
FDA Approves Axicabtagene Ciloleucel for Second-line Treatment of Large B-cell Lymphoma.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-axicabtagene-ciloleucel-for-second-line-treatment-of-large-b-cell-lymphoma.
American Society of Hematology.
"FDA Approves Axicabtagene Ciloleucel for Second-line Treatment of Large B-cell Lymphoma." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-axicabtagene-ciloleucel-for-second-line-treatment-of-large-b-cell-lymphoma
(label-accessed April 19, 2024).
"American Society of Hematology."
FDA Approves Axicabtagene Ciloleucel for Second-line Treatment of Large B-cell Lymphoma, 19 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-axicabtagene-ciloleucel-for-second-line-treatment-of-large-b-cell-lymphoma.
